Klaviyo Announces Pricing of Secondary Offering of 10,969,078 Shares of Series A Common Stock by Andrew Bialecki
BOSTON–(BUSINESS WIRE)–Klaviyo, Inc. (the “Company”) (NYSE: KVYO), the only CRM built for consumer brands, today announced the pricing of an underwritten... Read more.
ANEXT Bank Recorded S$44.9M Revenue in 2024, up 83.5%
The bank also saw a 207% increase in deposits and 280% increase in loans SINGAPORE–(BUSINESS WIRE)–ANEXT Bank, a Singapore digital wholesale bank licensed... Read more.
Li-Cycle Obtains Creditor Protection Under CCAA and Chapter 15
Company enters into $10.5 million debtor-in-possession financing facility (“DIP Facility”) term sheet with Glencore Li-Cycle and Glencore agree to “stalking... Read more.
Microba Announces Landmark GI Study Results From Over 4,600 Patients
Results at a glance: 71.4% of MetaXplore™ reports from 4,616 patients identified actionable results 41.9% tested positive for abnormal microbiome markers linked... Read more.
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance... Read more.
Renatus Tactical Acquisition Corp I Announces Pricing of Upsized $210 Million Initial Public Offering
CORAL GABLES, Fla.–(BUSINESS WIRE)–Renatus Tactical Acquisition Corp I (the “Company”) today announced the pricing of its upsized initial public... Read more.
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent... Read more.
Best’s Market Segment Report: AM Best Maintains Outlook on Philippine Non-Life Insurance Segment at Stable
SINGAPORE–(BUSINESS WIRE)–#insurance—AM Best has maintained its market segment outlook on the Philippine non-life insurance market at stable, citing... Read more.
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent... Read more.
Best’s Market Segment Report: AM Best Maintains Outlook on Philippine Non-Life Insurance Segment at Stable
SINGAPORE–(BUSINESS WIRE)–#insurance—AM Best has maintained its market segment outlook on the Philippine non-life insurance market at stable, citing... Read more.